Ropivacaine Hydrochloride (Naropin) Injection Shortage: Supply Updates and Manufacturer Status

What’s in Shortage

Ropivacaine Hydrochloride Injection, also known by the brand name Naropin, is currently listed on the FDA drug shortage database. This medication is categorized as an anesthesia product. The shortage affects various concentrations and presentations of the injection, including 2 mg/mL, 5 mg/mL, 7.5 mg/mL, and 10 mg/mL.

Which Manufacturers Are Affected

Several manufacturers are currently reporting varying levels of availability for Ropivacaine Hydrochloride:

• Caplin Steriles, Ltd. (Marketed by Baxter): Reports limited availability for certain 2 mg/1 mL and 5 mg/1 mL presentations. Other 5 mg/1 mL and 10 mg/1 mL presentations are currently available. (Contact: 888-229-0001)
• Eugia US LLC: Reports that specific 7.5 mg/1 mL and 10 mg/1 mL presentations are on backorder with a recovery date to be determined. Several other concentrations remain available. (Contact: 888-238-7880)
• Fresenius Kabi USA, LLC: Multiple presentations of Naropin (2 mg/1 mL, 5 mg/1 mL, 7.5 mg/1 mL, and 10 mg/1 mL) are currently unavailable, with some having no release date available at this time. However, several other specific NDC presentations remain available. (Contact: 888-386-1300)

Why There’s a Shortage

The official reason provided for this shortage is listed as “Other.” No further specific details regarding manufacturing or supply chain issues were disclosed in the source data.

What Patients Should Do

If you are scheduled for a procedure requiring anesthesia, please be aware of the following steps:

• Consult Your Healthcare Provider: Discuss any concerns regarding your treatment plan with your doctor or surgeon. They are best equipped to manage your care during a shortage.
• Speak with the Pharmacy: Hospital or clinic pharmacists can provide the most current information on local inventory and supply status.
• Contact Manufacturers: For specific supply inquiries or to check on the status of a particular presentation, you may use the contact numbers provided above.

Disclaimer: Patients should always consult their healthcare provider regarding medication changes or treatment alternatives.

Source

Information provided by the FDA Drug Shortage Database.

• Initial Posting Date: 12/22/2020
• Last Updated: 02/02/2026